Trials / Unknown
UnknownNCT02611232
Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- University of Oulu · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of the trial are to study whether daily treatment with liraglutide improves insulin secretion and glucose metabolism, and whether liraglutide treatment is tolerable and safe in subjects with preclinical type 1 diabetes aged 18-30 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Victoza® | Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months. |
| DRUG | Placebo | Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months. |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
- First posted
- 2015-11-20
- Last updated
- 2022-01-25
Locations
3 sites across 1 country: Finland
Source: ClinicalTrials.gov record NCT02611232. Inclusion in this directory is not an endorsement.